[Updating neonatal neurometabolic screening]
- PMID: 19240000
[Updating neonatal neurometabolic screening]
Abstract
The purpose of neurometabolic screening is the earliest possible detection of treatable disorders. The disorders currently offered to general population screening are phenylketonuria, congenital hypothyroidism, galactosemia, congenital adrenal hyperplasia, cystic fibrosis, biotinidase deficiency, maple syrup urine disease, sickle cell disease, homocystinuria. The methods used for these evaluations are mass spectroscopy and genetic testing.
Similar articles
-
[The advisory report 'Neonatal screening' from the Health Council of The Netherlands].Ned Tijdschr Geneeskd. 2005 Dec 17;149(51):2857-60. Ned Tijdschr Geneeskd. 2005. PMID: 16398167 Dutch.
-
State screening for metabolic disorders in newborns.Am Fam Physician. 1988 Apr;37(4):223-8. Am Fam Physician. 1988. PMID: 3358346
-
Newborn screening fact sheets.Pediatrics. 2006 Sep;118(3):e934-63. doi: 10.1542/peds.2006-1783. Pediatrics. 2006. PMID: 16950973
-
Neurometabolic diseases in the newborn.Clin Perinatol. 2006 Jun;33(2):411-79. doi: 10.1016/j.clp.2006.03.013. Clin Perinatol. 2006. PMID: 16765732 Review.
-
Current approaches to genetic metabolic screening in newborns.Curr Opin Pediatr. 1994 Dec;6(6):707-11. doi: 10.1097/00008480-199412000-00017. Curr Opin Pediatr. 1994. PMID: 7849819 Review.